PromoFectin-CRISPR: A new tool to improve your gene editing experiments

Rapidly generating precise, targeted modifications to a living genome is a long-standing goal for biomedical researchers. Achieving this would enable development of novel molecular therapies for human diseases through gene therapy, and allow engineering of transgenic plants and animals.

The development of the CRISPR-Cas technology allows scientists to edit genomes relatively quickly and relatively easily, providing a sophisticated, powerful tool to introduce a variety of genetic alterations (e.g. deletions, insertions, base pair mutations) into mammalians cells. This approach involves a synthetic, programmable guide RNA (gRNA) that is associated with a Cas9 nuclease. This tailored single guide RNA (sgRNA) can bind to a specific dsDNA sequence, bringing the CAS9 nuclease to a targeted region in the genome, where the nuclease then introduces a double-strand break in the DNA. By using the cell’s endogenous DNA repair mechanisms, it is possible to engineer very specific genomic changes.

A crucial step of any CRISPR workflow is delivering the sgRNA and Cas9 protein into the cytoplasm or nucleus of the target cell. Guide-RNA and Cas9 can be delivered into cells as (plasmid) DNA, mRNA, or as pre-formed ribonucleoprotein complexes (RNPs).

Delivering the CRISPR-Cas constructs into hard-to-transfect cell types such as primary cells, stem cells or neurons can be quite challenging. Various methods have been developed to efficiently introduce nucleic acids or RNPs into primary cells and cell lines. This must be done while maintaining cell heath and morphology, along with avoiding off-target effects.

The PromoCell PromoFectin family of transfection reagents provides complete delivery solutions for successful CRISPR/Cas9 genome editing. Our high-quality reagents and optimized protocols for each product option will help you significantly improve your genome editing results with multiple – even difficult-to-transfect – cell types. In contrast to harsh, expensive but frequently used methods such as electroporation, our economic PromoFectins mediate a gentle transfection with lowest cytotoxicity.

CRISPR-Cas component delivery options:

DNA
Plasmids carrying the coding sequences for the gRNA and Cas9 enter the nucleus and are transcribed into RNA (gRNA or mRNA that will be translated into Cas9) that enter the cytoplasm. Use:

  • PromoFectin
  • PromoFectin-HUVEC
  • PromoFectin-Hepatocyte
  • PromoFctin-Macrophage

mRNA
The Cas9-encoding mRNA will be directly delivered into the cytoplasm and then translated. Use:

  • PromoFectin-mRNA

Ribonucleoprotein complex (RNP)
Pre-complexed RNPs do not require any transcription or translation and are delivered directly to the cytoplasm or to the nucleus. Use:

  • PromoFectin-CRISPR

To learn more about PromoCell’s PromoFectin Transfection Reagents, visit our webpage , or get in touch with our scientific support service at the toll-free number 0800 -776 66 23.

Test our PromoFectins in your research now using our 50-100% OFF year end promotion!

Effectively transfect your cells with our PromoFectin reagents

Request Sample

Choose your Region

Please choose your region for an optimized website experience. So we can provide you with the most useful information for your country.

  1. North America
    1. Canada
    2. United States
  2. Europe
    1. Albania
    2. Austria
    3. Belgium
    4. Bosnia-Herzogovina
    5. Bulgaria
    6. Croatia
    7. Czech Republic
    8. Denmark
    9. Estonia
    10. Finland
    11. France
    12. Germany
    13. Greece
    14. Hungary
    15. Ireland
    16. Italy
    17. Latvia
    18. Liechtenstein
    19. Lithuania
    20. Luxembourg
    21. Macedonia
    22. Monaco
    23. Netherlands
    24. Norway
    25. Poland
    26. Portugal
    27. Romania
    28. Serbia
    29. Slovakia
    30. Slovenia
    31. Spain
    32. Sweden
    33. Switzerland
    34. United Kingdom
  3. Asia
    1. Bangladesh
    2. China
    3. Hong Kong (incl. Macau)
    4. India
    5. Indonesia
    6. Israel
    7. Japan
    8. Malaysia
    9. Nepal
    10. Singapore
    11. South Korea
    12. Sri Lanka
    13. Taiwan
    14. Thailand
  4. Oceania
    1. Australia
    2. New Zealand